Conference
A phase IIA clinical trial to evaluate a reversible Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
Authors
Lee N; Li Y; Mao Y; Liu G; Li J; Liu Q
Volume
42
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
June 1, 2024
Name of conference
Special Clinical Science Symposia
Conference place
ELECTR NETWORK
Conference start date
May 29, 2024
Conference end date
May 29, 2024
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
16
ISSN
0732-183X